Health Care · Surgical & Medical Instruments & Apparatus

OFIX Orthofix Medical Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 884624127 filings
Russell 2000

OFIX at a glance

Orthofix Medical Inc. (OFIX, SEC CIK 884624) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Orthofix Medical Inc. (OFIX) reported revenue of $822.3 million (up 2.9% from FY2024) and a net loss of $92.2 million. Diluted EPS was -$2.33.
  • As of September 30, 2026, 22 institutional investment managers tracked by SignalX reported holding Orthofix Medical Inc. (OFIX) shares worth $111.9 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Juniper Investment Company, LLC on November 11, 2026 of 14,803 shares at $7.04 per share.
  • In the last 90 days, OFIX insiders reported 4 open-market purchases ($7.8M) and 5 open-market sales ($2.7M) on Form 4, a net purchase of $5.1M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$822.3M
+2.9% vs prior year
Insiders · 90 days
4 buys · 5 sells
Net +$5.1M
13F holders
22 funds
$111.9M · −3 vs prior quarter
Latest 8-K
Nov 9, 2026
Item 7.01 · Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $207.9M, up 1.1% YoY from $205.6M
  • Operating margin 0.7% vs (8.3%) YoY, net loss margin (2.9%) vs (11.1%)
  • Best segment Global Limb Reconstruction, $36.4M, up 8.5%; worst Spinal Implants, Biologics and Enabling Technologies, $107.4M, down 1.1%
  • Cash $86.9M vs $85.1M at December 31, 2025; nine-month operating cash flow $(23.5)M
  • $65.0M Term B Loan funded; FDA reclassification headwind, heightened competition and pricing pressure for bone stimulators

Risk Factors

  • Regulatory risk: FDA reclassification from Class III to Class II lowers entry barriers for bone growth stimulators
  • Competitive risk: New entrants could create pricing pressure and erode Orthofix’s market share
  • Operating risk: Higher research, clinical, marketing, and surveillance spending could reduce margins
  • Market risk: Increased competitor promotion could reduce demand for Orthofix products

AI summary of the OFIX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 9, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Investor-relations presentation designated for use with investors and analysts through December 31, 2026
  • Exhibit 99.2 likely outlines Orthofix’s corporate narrative, strategy, and investor messaging for fiscal 2026

Item 2.02: Results of Operations and Financial Condition

  • Q3 results covered the period ended September 30, 2026, with detailed financial figures contained in Exhibit 99.1
  • Management emphasizes adjusted EBITDA, free cash flow, constant-currency sales and adjusted earnings for operating performance analysis

Item EX-99.1: Item EX-99.1

  • Q3 net sales $207.9M, up 1.1% reported, while pro forma constant-currency growth reached 2.3%
  • Spine growth weakened to 0.9%, offset by Limb Reconstruction growth of 8.5% and Therapeutic Solutions growth of 4.5%

Item EX-99.2: Item EX-99.2

  • Q3 2026 sales $207.9M, up 2% year over year constant currency, with Limb Reconstruction +9.4% and Therapeutic Solutions +4.5%
  • U.S. Spine sales fell 4.3%, reflecting market softness, supplier delays, inventory constraints and instrument-set shortages
Filed Aug 5, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 net sales $210.9M, up 3.8% reported and 4.7% pro forma constant currency, supporting improved operating momentum
  • Global Limb Reconstruction grew 13.2%, while Global Spine increased 3.5% pro forma, offsetting weaker portfolio areas

Item 2.02: Results of Operations and Financial Condition

  • Q2 results for quarter ended June 30, 2026 announced August 5, 2026, with detailed figures in Exhibit 99.1
  • Management emphasizes adjusted EBITDA, excluding merger, M6, restructuring, litigation, acquisition and employee transition costs

Item 7.01: Regulation FD Disclosure

  • Investor relations presentation planned for use with investors and analysts through fiscal 2026
  • Exhibit 99.2 likely contains the company’s current investor messaging and key performance materials

Item EX-99.2: Item EX-99.2

  • Q2 2026 net sales $210.9M, up 5% YoY pro forma constant currency
  • Adjusted EBITDA $20.1M, 10% margin, versus $20.6M in Q2 2025
Filed Jul 2, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • CMS withdrew reimbursement changes for non-invasive bone growth stimulators effective May 18, 2026
  • Medicare billing for HCPCS codes E0747, E0748 and E0760 returns to pre-reclassification treatment

AI summaries of OFIX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for OFIX

Don't miss the next OFIX filing

  • Alerts as it files. A push when OFIX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut OFIX, by share count.
  • Ask anything. An AI agent that reads every OFIX filing and answers with sources.

OFIX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Juniper Investment Company, LLCBuyNov 11, 2026$7.04
Juniper Investment Company, LLCBuyNov 9, 2026$7.41
Fisher PatrickSellNov 2, 2026$9.07
Fisher PatrickSellOct 1, 2026$9.44
Juniper Investment Company, LLCSellSep 21, 2026$8.86
Juniper Investment Company, LLCBuySep 21, 2026$8.86
Juniper Investment Company, LLCBuySep 18, 2026$8.74
Juniper Investment Company, LLCSellSep 18, 2026$8.74

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$746.6M$799.5M$822.3M
Gross Profit-$545.9M$566.0M
Operating Income--$84.6M-$81.4M
Net Income--$126.0M-$92.2M
Gross Margin-68.3%68.8%
Op. Margin--10.6%-9.9%
Net Margin--15.8%-11.2%
Balance Sheet
Total Assets$925.3M$893.3M$850.6M
Equity$598.7M$503.1M$450.0M
ROE--25.0%-20.5%
Per Share
EPS-$-3.30$-2.33
Cash Flow
Operating CF-$25.8M$33.3M
CapEx$60.3M--

Source: XBRL data in Orthofix Medical Inc. (OFIX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate OFIX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
OFIX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202622$111.9M
Q2 202625$103.8M
Q1 202623$117.2M
Q4 202523$160.0M
Q3 202525$163.7M
Q2 202526$124.0M
Q1 202522$89.7M
Q4 202418$83.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 184 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

OFIX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 12, 2026--
8-KNov 9, 2026Analysis-
10-QNov 9, 2026Analysis
4Nov 4, 2026--
4Oct 5, 2026--
4Sep 23, 2026--
4Sep 22, 2026--
4Sep 3, 2026--
4Aug 20, 2026--
4Aug 18, 2026--
10-QAug 5, 2026Analysis
8-KAug 5, 2026Analysis-
8-KJul 2, 2026Analysis-
4Jun 22, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
4Jun 12, 2026--
8-KJun 11, 2026Analysis-
4May 29, 2026-

Related Health Care companies

All Health Care →

OFIX SEC filings: frequently asked questions

Are OFIX insiders buying or selling?

In the last 90 days, Orthofix Medical Inc. (OFIX) officers, directors and 10% owners reported 4 open-market purchases worth $7.8 million by 1 insider and 5 open-market sales worth $2.7 million by 2 insiders on Form 4, a net purchase of $5.1 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold OFIX stock?

As of September 30, 2026, the largest Orthofix Medical Inc. (OFIX) holders among the 13F filers tracked by SignalX were BlackRock ($36.4 million), Vanguard Capital Management LLC ($16.0 million), State Street Corp ($9.4 million), Millennium Management ($8.9 million), Dimensional Fund Advisors ($6.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was OFIX's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Orthofix Medical Inc. (OFIX) reported revenue of $822.3 million (up 2.9% from FY2024) and a net loss of $92.2 million. Diluted EPS was -$2.33. The figures come from the XBRL data in the 10-K.

What did OFIX report in its latest 8-K?

Orthofix Medical Inc. (OFIX) filed an 8-K on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.02 (Results of Operations and Financial Condition). Investor-relations presentation designated for use with investors and analysts through December 31, 2026.

What are the latest OFIX SEC filings?

Orthofix Medical Inc. (OFIX) filed its latest 10-K annual report on February 24, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 12, 2026.

What is OFIX's SEC CIK number?

Orthofix Medical Inc. (OFIX)'s SEC Central Index Key (CIK) is 884624. EDGAR lists every OFIX filing under that number.

Ask anything about OFIX

The research agent reads OFIX's filings, financials, insider trades and 13F holders, then answers with sources.